...
首页> 外文期刊>BJU international >Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial
【24h】

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial

机译:前列腺癌症发生率和死亡率的延长随访,前列腺癌,肺,结直肠癌和卵巢随机癌症筛选试验中的参与者

获取原文
获取原文并翻译 | 示例

摘要

Objective To examine prostate cancer (PCa) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Patients and Methods Patients aged 55-74 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate-specific antigen (PSA) tests and four annual digital rectal examinations. The patients were followed for PCa incidence and for mortality via active follow-up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow-up, trial abstractors recorded the mode of diagnosis (screen-detected, symptomatic, other). Results A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow-up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care) PCa cancer deaths, giving rates (per 10 000 person-years) of 5.5 and 5.9, respectively, and a rate ratio (RR) of 0.93 (95% confidence interval [CI] 0.81-1.08; P = 0.38). The RR for overall PCa incidence was 1.05 (95% CI 1.01-1.09). The RRs by Gleason category were 1.17 (95% CI 1.11-1.23) for Gleason 2-6, 1.00 (95% CI 0.93-1.07) for Gleason 7 and 0.89 (95% CI 0.80-0.99) for Gleason 8-10 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post-screening, these percentages were 18% in each arm. Conclusion After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2-6 disease and a significant reduction in Gleason 8-10 disease in the intervention compared with the usual care arm.
机译:目的在随机前列腺,肺,结直肠和卵巢(PLCO)癌症筛查试验中,检查前列腺癌(PCA)发病率和死亡率。在1993年至2001年至2001年间,患者和方法55-74岁的患者在1993年至2001年之间进行了干预或通常的护理手臂。干预臂中的患者接受了六年年前前列腺特异性抗原(PSA)测试和四个年度数字直肠检查。患者通过活跃的后续过程和与国家癌症登记处和国家死亡指数的联系,患者进行PCA发病率和死亡率。对于通过积极随访确定的癌症,试验摘要录制了诊断模式(屏幕检测,症状,其他)。结果总共38个340名患者随机分配到干预臂,3833〜343到通常的护理臂。死亡率的中位后续行动为16.9(干预)和16.7岁(常规护理)。 333例(干预)和352(常规护理)PCA癌症死亡,分别提供5.5和5.9的率(每10 000人),率比(RR)为0.93(95%置信区间[CI] 0.81-1.08; p = 0.38)。整体PCA发病率的RR为1.05(95%CI 1.01-1.09)。 Gleason 7和0.89(95%CI 0.93-1.07)的Gleason 7和0.89(95%CI 0.93-1.07)的Gleason类别为1.17(95%CI 1.11-1.23)。通过检测方式,在试验的筛选阶段,13%的干预臂与27%的常规护理箱案件有症状;筛选后,每只臂的这些百分比为18%。结论近17年的中位后续后,与通常的护理手臂相比,介入的PCA死亡率没有显着降低。与通常的护理手臂相比,Glason 2-6疾病的肠胃2-6型疾病显着增加了Glason 8-10疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号